Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.57 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.57 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.56 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.56 |
| ▸ | CLEC4M | Q9H2X3 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15780060 | 0.86 | GABRA1 (0.58) | GABRA1GABRB2GABRB1GABRA3CLEC4M | |
| SCHEMBL15361974 | 0.80 | HPGD (0.49) | MEN1KMT2AALDH1A1HPGDHSD17B10 | |
| SCHEMBL15361973 | 0.80 | HPGD (0.49) | MEN1KMT2AALDH1A1HPGDHSD17B10 | |
| SCHEMBL376662 | 0.79 | GABRA1 (0.69) | GABRA1GABRB2GABRB1GABRA3CLEC4M | |
| SCHEMBL29475801 | 0.79 | GABRA1 (0.69) | GABRA1GABRB2GABRB1GABRA3CLEC4M | |
| Hydrochloric Acid SCHEMBL30417898 | 0.78 | GABRA1 (0.67) | GABRA1GABRB2GABRB1GABRA3CLEC4M | |
| Hydrochloric Acid SCHEMBL29008098 | 0.78 | GABRA1 (0.67) | GABRA1GABRB2GABRB1GABRA3CLEC4M | |
| SCHEMBL28287752 | 0.76 | GABRA1 (0.66) | GABRA1GABRB2GABRB1GABRA3CLEC4M | |
| SCHEMBL3514702 | 0.76 | TSHR (0.56) | MEN1KMT2AALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL1430520 | 0.74 | GABRA1 (0.63) | GABRA1GABRB2GABRB1GABRA3CLEC4M |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748612-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-10 | — | — | US | disclosed |
| EP-2201010-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2013-11-06 | — | — | EP | disclosed |
| US-20130178496-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2013-07-11 | — | — | US | disclosed |
| US-8410132-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410132-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-02 | — | — | US | disclosed |
| US-20130018070-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130018070-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-17 | — | — | US | disclosed |
| US-8188283-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20100261750-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-14 | — | — | US | disclosed |
| EP-2201010-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009036412-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178496-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, ABCB1, ABCC1 | GABRA1 923/4885GABRB2 265/4885GABRB1 249/4885 |
| US-20130018070-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, ABCB1, ABCC1 | GABRA1 923/4885GABRB2 265/4885GABRB1 249/4885 |
| US-20100261750-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | CFTR, ABCB1, ABCC1 | GABRA1 923/4885GABRB2 265/4885GABRB1 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.